Apatinib (YN968D1) is a novel and high selectivity inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase, which will block the downstream signal transduction of VEGFR2 at the cellular level.4 Apatinib exerts promising antitumoral effect in various tumors.5, 6, 7 As shown in a third-phase clinical trial, Apatinib has been proven to be a safe and effective drug in patients with advanced gastric cancer.8 However, the antitumoral effect of Apatinib in human osteosarcoma has never been reported. This evidence concerns the gene KDR and gastric cancer.